Profile data is unavailable for this security.
About the company
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimer’s disease (AD) and UB-312, which targets the pathological process of Parkinson’s disease (PD) and other so-called synucleinopathies.
- Revenue in USD (TTM)0.00
- Net income in USD-56.94m
- Incorporated2021
- Employees57.00
- LocationVaxxinity Inc1717 Main Street, Suite 3388DALLAS 75201United StatesUSA
- Phone+1 (254) 244-5739
- Fax+1 (302) 636-5454
- Websitehttps://vaxxinity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexgel Inc | 4.09m | -3.16m | 13.70m | 19.00 | -- | 2.69 | -- | 3.35 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Dominari Holdings Inc | 2.04m | -22.88m | 13.75m | 26.00 | -- | 0.2599 | -- | 6.74 | -4.44 | -4.44 | 0.3899 | 8.92 | 0.0305 | -- | 0.3829 | 78,423.08 | -34.20 | -26.82 | -35.10 | -27.45 | -- | -- | -1,122.22 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 13.82m | 22.00 | -- | 2.50 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| GlucoTrack Inc | 0.00 | -7.10m | 14.30m | 6.00 | -- | 3.49 | -- | -- | -0.3394 | -0.3394 | 0.00 | 0.153 | 0.00 | -- | -- | 0.00 | -193.30 | -94.01 | -294.60 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.0578 | -- | -- | -- | -60.02 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 14.31m | 12.00 | -- | 0.6874 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.72m | 14.32m | 16.00 | -- | 2.41 | -- | -- | -2.60 | -2.60 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -79.13 | -- | -95.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 14.44m | 46.00 | -- | 0.5398 | -- | 0.3374 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Vaxxinity Inc | 0.00 | -56.94m | 14.53m | 57.00 | -- | 1.08 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| Tonix Pharmaceuticals Holding Corp | 7.77m | -116.66m | 14.95m | 103.00 | -- | 0.0983 | -- | 1.93 | -8.62 | -8.62 | 0.4572 | 1.80 | 0.0409 | -- | -- | 75,417.48 | -61.38 | -59.46 | -68.01 | -65.92 | 38.97 | -- | -1,501.78 | -5,126.73 | 1.81 | -- | 0.0779 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Cardio Diagnostics Holdings Inc | 17.07k | -8.38m | 15.07m | 7.00 | -- | 4.85 | -- | 882.87 | -0.7363 | -0.7363 | 0.0014 | 0.144 | 0.0032 | -- | 6.88 | 2,438.57 | -156.40 | -- | -211.46 | -- | -- | -- | -49,073.46 | -- | -- | -5.45 | 0.1122 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.03m | 15.14m | 3.00 | -- | 2.86 | -- | -- | -0.0176 | -0.0176 | 0.00 | 0.0307 | 0.00 | -- | -- | 0.00 | -28.92 | 27.48 | -30.91 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| Mannatech Inc | 131.96m | -2.24m | 15.21m | 213.00 | -- | 1.43 | -- | 0.1153 | -1.21 | -1.21 | 70.53 | 5.64 | 2.92 | 1.99 | 854.08 | 619,507.10 | -4.96 | 4.39 | -12.90 | 9.16 | 77.95 | 77.87 | -1.70 | 1.72 | 0.5093 | -5.81 | 0.1226 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
| Oncotelic Therapeutics Inc | 70.00k | -7.90m | 15.51m | 22.00 | -- | 1.28 | -- | 221.54 | -0.02 | -0.02 | 0.0002 | 0.0304 | 0.0021 | -- | 3.61 | 3,181.82 | -24.82 | -25.03 | -49.08 | -48.76 | -- | -- | -11,722.94 | -1,692.93 | -- | -0.4788 | 0.5199 | -- | -- | -- | -255.12 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Dec 2023 | 3.00m | 2.66% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.51m | 2.22% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.31m | 2.05% |
| Geode Capital Management LLCas of 31 Dec 2023 | 842.01k | 0.75% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 799.27k | 0.71% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 338.10k | 0.30% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 334.50k | 0.30% |
| Creative Planning LLCas of 31 Dec 2023 | 285.09k | 0.25% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 229.10k | 0.20% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 219.93k | 0.20% |
